Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

November 6th, 2018

New Zilver® PTX® global data analysis reveals long-term benefit, real-world outcomes

Study finds 91 percent freedom from TLR at one year and 76 percent at five years, including complex lesions

Bloomington, Ind. – Cook Medical introduced the results from an aggregated data analysis at the Vascular Interventional Advances (VIVA) conference, highlighting the Zilver® PTX® Drug-Eluting Peripheral Stent (DES) benefits in challenging patient populations. When considering various patient and lesion factors, the analysis concluded that risk factors such as Rutherford classification, sex, calcification and diabetes did not have a significant impact on the target lesion revascularization (TLR) rate in patients treated with the Zilver PTX stent.1

“It’s generally thought that sex, calcification and diabetes may have an impact on TLR, but this data demonstrates that these factors do not,” said Mark Breedlove vice president of Cook Medical’s Vascular division. “In this global analysis of Zilver PTX patients, these characteristics did not have a significant impact on TLR.”

The global data analysis on the world’s first drug-eluting stent in the superficial femoral artery (SFA) included nearly 2,400 patients from 16 countries who participated in one of five Zilver PTX studies. This included three pre-market studies in North America, Asia and Europe and two post-market studies in the United States and Japan.2,3,4 The study sought to identify the impact of patient and lesion factors on freedom from TLR at one year. The results indicated that factors typically impacting reintervention rates did not have an impact on the reintervention rates for patients treated with the Zilver PTX stent.

“With an unrivaled five years of data gathered from these studies, Zilver PTX has shown long-term benefits in real-world outcomes. This is a significant amount of data that informs how we continue to work alongside physicians to fight this disease,” said Breedlove. “We’re committed to helping patients who deal with the impact of PAD on their lives.”

Zilver PTX5 was the first DES in the United States used in the treatment of PAD and is the only drug-eluting superficial femoral artery stent with five-year data. As previously published, patients treated with the Zilver PTX stent achieved a higher percentage of freedom from TLR compared to standard of care endovascular treatment, resulting in 91 percent freedom from TLR at one year and 76 percent at five years.2 Zilver PTX has been shown to cut reinterventions by nearly half through five years compared to both bare metal Zilver stents and a combination of bare-metal Zilver stents and percutaneous transluminal angioplasty (PTA).2

About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at, and for the latest news, follow us on Twitter, Facebook and LinkedIn.

Drs. Dake and Yokoi are paid consultants for Cook Medical.

  1. Dake M. Zilver PTX global data analysis highlights DES benefits in challenging patient populations. Presented at: VIVA;November 6, 2018; Las Vegas, NV.
  2. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX.Circulation. 2016;133(15):1472-1483.
  3.  Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol Intv. 2013;61(24):2417-2427.
  4. Yokoi H, Ohki T, Kichikawa, K, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 12-month results. J Am Coll Cardiol Intv. 2016;9(3):271-277.
  5. CAUTION: U.S. federal law restricts this device to sale by or on the order of a physician (or properly licensed practitioner). Use of this drug-eluting peripheral stent carries the risks associated with peripheral artery stenting, including vascular complications and/or bleeding events. Refer to the Instructions for Use (IFU) for full prescribing information including information on potential adverse events, contraindications, warnings, precautions, and summary of clinical data.